Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Stemcentrx LlcfiledCriticalAbbvie Stemcentrx Llc
Publication of AR110347A1publicationCriticalpatent/AR110347A1/en
Se proveen anticuerpos y conjugados de fármaco y anticuerpo anti-KREMEN2, y métodos para usar dichos anticuerpos y conjugados de fármaco y anticuerpo anti-KREMEN2 para el tratamiento del cáncer. ADN, vector y célula huésped.Antibodies and anti-KREMEN2 antibody and drug conjugates are provided, and methods for using said antibodies and anti-KREMEN2 drug and antibody conjugates for cancer treatment. DNA, vector and host cell.
ARP170103465A2016-12-092017-12-12
ANTI-KREMEN2 ANTIBODIES AND METHODS FOR USE
AR110347A1
(en)